4th Microbiome R&D and Business Collaboration Forum: Europe

Meet up with our experts during the 4th Mircobiome R&D and Business collaboration Forum: Europe. This event will be held on 3 – 4 April, 2017 in Amsterdam!

Meet us at stand #15 and discover what our latest technologies can do you for your product. You are very welcome to arrange a meeting with one of us in advance. During this interactive event, we will share our latest insights into screening and substantiation of ingredients with gut health benefits and skin microbiota.

Meet our experts during this Microbiome event:

The relation between ichthyosis vulgaris, host genotype and skin microbiota”

Dr. Sacha van Hijum, Principal Scientist Microbiomics

DAY 1 MONDAY 3TH APRIL 2017 1.00-1.15 pm

Filaggrin (FLG) is a structural skin protein highly abundant in histidine that, upon degradation, serves as the main source of “natural moisturizing factors”, which allows the outermost skin layers to stay hydrated. Mutations in the FLG gene might lead to aberrant skin barrier function, and we questioned if variation in this epidermal barrier gene can cause microbial changes. Microbiota analysis showed that FLG-/- individuals have a lower relative abundance of proteolytic Gram-positive anaerobe cocci.

The Radboudumc Dermatology group together with NIZO coworkers proved that, in a recently developed in vitro system that mimics human stratum corneum for bacterial growth, that reduction of these taxa was indeed due to FLG deficiency. Furthermore, functional analysis revealed that microbiome-derived genes involved in metabolic pathways for histidine utilization as carbon source are underrepresented in the FLG-/- microbiome. Collectively, our data show for the first time how a specific genetic defect in the skin barrier can shape the composition of cutaneous microbial communities.

“Integrated approach for screening and substantiation of ingredients with a gut health benefit “– Alwine Kardinaal, Expertise Group Leader Nutrition & Health

DAY 2 TUESDAY 4TH APRIL 2017 3.30-4.00 pm

  • Relevance of in vitro screening assays for in vivo benefits
  • Use of human challenge models to evaluate effects in healthy populations
  • Clinically relevant outcomes and mechanistic insights
  • How to investigate the role of the small intestinal microbiome: use of a non-invasive sampling tool
  • Integrating information from in vitro and in vivo studies for better predictions in the future
  • High Throughput Screening
  • Probiotic production

4th Mircobiome R&D and Business collaboration Forum: Europe

The 2017 Microbiome R&D and Business Collaboration Forum: Europe will feature extended panel discussions and round table debates. Plus, there will be venture capital pitch and partner sessions where you can source that all important financing to transform your research into a viable product. With over 60 talks and 7 hours dedicated to networking, the 2017 Forum is not one to miss.

Register here. Interested in a meeting? Contact Nils Hijlkema.

This website uses cookies

Close